Drug intelligence / Profile preview

VARA

Development stage
Preclinical
Lead developer
Virginia Tech
Modality
Small Molecules
Administration
Oral
01

Overview

VARA is an experimental combination of vitamin A metabolites consisting of retinyl palmitate (a storage form of vitamin A) and all-trans-retinoic acid (tRA). In the studied formulation, it is prepared as a mixture where tRA represents 10% of the retinol equivalent provided by retinyl palmitate (specifically 11.2 mg/kg retinyl palmitate mixed with 0.6 mg/kg tRA). Developed for research purposes, particularly in the context of systemic lupus erythematosus (SLE), VARA is used to investigate the complex and sometimes paradoxical effects of vitamin A on autoimmune pathogenesis. While retinoids like tRA are known to have anti-inflammatory properties and can ameliorate lupus nephritis, research indicates that the VARA combination may exacerbate neuroinflammation and neurodegeneration in lupus-prone MRL/lpr mice, leading to increased brain weight, astrogliosis, and immune complex deposition in the central nervous system.

Other names
retinyl palmitate + all-trans-retinoic acidVitamin A + Retinoic Acidretinol + tRA mixture
02

Targets

RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)RXRA (Retinoid X receptor alpha)RXRB (Retinoid X receptor beta)RXRG (RXRγ)RAR (Retinoic acid receptor)

Beyond the preview

Go deeper on VARA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VARA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call